Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy
Open Access
- 28 June 2018
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 1-14
Abstract
The excessive amounts of immunosuppressive factors present in a tumor microenvironment (TME) reduce the effectiveness of cancer vaccines. The main objective of our research was to improve the effectiveness of dendritic cell (DC)-based immunotherapy or chemoimmunotherapy composed of cyclophosphamide (CY) and DCs by application of lentivectors encoding shRNA specific to IL-10 (shIL10 LVs) in murine colon carcinoma MC38 model. The efficacy of shIL10 LVs in silencing of IL-10 expression was measured both in vitro and in vivo using Real-Time PCR and ELISA assays. In addition, the influence of intratumorally inoculated lentivectors on MC38 tumor microenvironment was examined using flow cytometry method. The effect of applied therapeutic schemes was determined by measurement of tumor growth inhibition and activation state of local and systemic immune response. We observed that intratumorally inoculated shIL10 LVs transduced tumor and TME-infiltrating cells and reduced the secretion of IL-10. Application of shIL10 LVs for three consecutive weeks initiated tumor growth inhibition, whereas treatment with shIL10 LVs and BMDC/TAg did not enhance the antitumor effect. However, when pretreatment with CY was introduced to the proposed scheme, we noticed high MC38 tumor growth inhibition accompanied by reduction of MDSCs and Tregs in TME, as well as activation of potent local and systemic Th1-type antitumor response. The obtained data shows that remodeling of TME by shIL10 LVs and CY enhances DC activity and supports them during regeneration and actuation of a potent antitumor response. Therefore, therapeutic strategies aimed at local IL-10 elimination using lentiviral vectors should be further investigated in context of combined chemoimmunotherapies.Keywords
Funding Information
- Ministerstwo Edukacji i Nauki (N N401 316239)
- Narodowe Centrum Nauki (2014/15/N/NZ4/04817)
This publication has 40 references indexed in Scilit:
- Clinical use of lentiviral vectorsLeukemia, 2018
- Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapyImmunologic Research, 2011
- IL-10 Elicits IFNγ-Dependent Tumor Immune SurveillanceCancer Cell, 2011
- The Role of Skin-Derived Dendritic Cells in CD8+ T Cell Priming Following Immunization with LentivectorsThe Journal of Immunology, 2010
- Interleukin‐10: new perspectives on an old cytokineImmunological Reviews, 2008
- Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.Oncology Reports, 2007
- Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integrationNature Biotechnology, 2006
- Ammonium Trichloro(dioxoethylene-o,o′)tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine LoopCancer Research, 2004
- Loss of Tumorigenicity of Murine Colon Carcinoma MC38/0 Cell Line after Transduction with a Retroviral Vector Carrying Murine IL-12 GenesFolia Biologica, 2004
- Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor AntibodyJournal of Experimental Medicine, 2002